AC
ADIL

Armistice Capital’s Adial Pharmaceuticals ADIL Stock Holding History

Armistice Capital’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-102,178
Closed -$562K – 265
2025
Q4 		$562K Buy
+102,178
New +$827K 0.01% 208
2024
Q1 		– Sell
-6,360
Closed -$296K – 338
2023
Q4 		$296K Buy
+6,360
New +$349K ﹤0.01% 220
2022
Q2 		– Sell
-2,908
Closed -$3.65M – 177
2022
Q1 		$3.65M Buy
+2,908
New +$3.98M 0.07% 87

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Armistice Capital's ADIL Position: Q1 2026 in Review

Armistice Capital sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 102,178 shares — an estimated $562K sold.

Armistice Capital first reported a position in ADIL in Q1 2022 and held it in 3 quarters. The position peaked at $3.65M in Q1 2022. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Armistice Capital reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Armistice Capital sold 102,178 Adial Pharmaceuticals shares in Q1 2026, an estimated $562K.
  • Armistice Capital first reported a position in Adial Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Armistice Capital's Adial Pharmaceuticals position peaked at $3.65M in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.